158 related articles for article (PubMed ID: 36994850)
1. hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer.
Hu XQ; Zhang BY; Hua T
J Int Med Res; 2023 Mar; 51(3):3000605231163780. PubMed ID: 36994850
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
3. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
5. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
8. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
9. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
10. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
11. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
12. hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.
Zhang J; Yin D; Li H
Oncol Rep; 2014 Nov; 32(5):2199-206. PubMed ID: 25175513
[TBL] [Abstract][Full Text] [Related]
13. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
Zhao H; Li N; Pang Y; Zhao J; Wu X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
[TBL] [Abstract][Full Text] [Related]
14. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
15. DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Connor JP; Felder M; Kapur A; Onujiogu N
BMC Cancer; 2012 May; 12():176. PubMed ID: 22583667
[TBL] [Abstract][Full Text] [Related]
16. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
18. Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway.
Chu L; Wang F; Zhang W; Li HF; Xu J; Tong XW
Technol Cancer Res Treat; 2020; 19():1533033820977535. PubMed ID: 33302812
[TBL] [Abstract][Full Text] [Related]
19. [Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300].
Wang A; Li J; Li H
Zhonghua Fu Chan Ke Za Zhi; 2014 Mar; 49(3):213-7. PubMed ID: 24820308
[TBL] [Abstract][Full Text] [Related]
20. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
